• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年和体弱房颤患者使用直接口服抗凝剂:抗凝服务的优势

Direct Oral Anticoagulants in Old and Frail Patients with Atrial Fibrillation: The Advantages of an Anticoagulation Service.

作者信息

Vedovati Maria Cristina, Agnelli Giancarlo

机构信息

Internal Vascular and Emergency Medicine-Stroke Unit, University of Perugia, 06129 Perugia, Italy.

IRCCS Istituti Scientifici Maugeri, 27100 Pavia, Italy.

出版信息

J Pers Med. 2022 Aug 20;12(8):1339. doi: 10.3390/jpm12081339.

DOI:10.3390/jpm12081339
PMID:36013288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9410430/
Abstract

Despite the recent advancements, oral anticoagulation is still challenging in some patients and this is the case for old and frail patients. The large majority of frail patients with atrial fibrillation should receive anticoagulation since the associated benefits outweigh the risk of bleeding. A multidisciplinary consensus document on the use and prescription of direct oral anticoagulants (DOACs) in older and frail patients with atrial fibrillation has been recently published. In this manuscript we provide a comment on this document and add insights into the management of these patients. The new DOAC age had imposed a paradigm shift in the management of patients with the need for clinically-oriented services rather than laboratory-oriented services. In this paper we provide tools for a structured patient-oriented DOACs treatment service supported by a multidisciplinary approach.

摘要

尽管最近有了进展,但口服抗凝治疗在一些患者中仍然具有挑战性,老年和体弱患者就是如此。绝大多数患有房颤的体弱患者都应接受抗凝治疗,因为相关益处大于出血风险。最近发表了一份关于老年和体弱房颤患者使用和处方直接口服抗凝剂(DOACs)的多学科共识文件。在本手稿中,我们对该文件发表评论,并补充对这些患者管理的见解。新的DOAC时代在需要临床导向服务而非实验室导向服务的患者管理中引发了范式转变。在本文中,我们提供了通过多学科方法支持的以患者为导向的结构化DOACs治疗服务工具。

相似文献

1
Direct Oral Anticoagulants in Old and Frail Patients with Atrial Fibrillation: The Advantages of an Anticoagulation Service.老年和体弱房颤患者使用直接口服抗凝剂:抗凝服务的优势
J Pers Med. 2022 Aug 20;12(8):1339. doi: 10.3390/jpm12081339.
2
Use and Prescription of Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Multidisciplinary Consensus Document.老年和体弱房颤患者直接口服抗凝剂的使用与处方:多学科共识文件
J Pers Med. 2022 Mar 15;12(3):469. doi: 10.3390/jpm12030469.
3
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.直接口服抗凝药与华法林在心房颤动患者中的比较:按年龄和性别进行交互测试的随机临床试验的患者水平网络荟萃分析。
Circulation. 2022 Jan 25;145(4):242-255. doi: 10.1161/CIRCULATIONAHA.121.056355. Epub 2022 Jan 5.
4
The Introduction of Direct Oral Anticoagulants Has Not Resolved Treatment Gaps for Frail Patients With Nonvalvular Atrial Fibrillation.直接口服抗凝剂的引入并未解决非瓣膜性心房颤动虚弱患者的治疗差距。
Can J Cardiol. 2022 Jan;38(1):77-84. doi: 10.1016/j.cjca.2021.09.021. Epub 2021 Dec 20.
5
Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation.直接口服抗凝剂在心力衰竭合并心房颤动患者中的出血风险。
Circ Cardiovasc Qual Outcomes. 2021 Feb;14(2):e007230. doi: 10.1161/CIRCOUTCOMES.120.007230. Epub 2021 Feb 5.
6
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation.直接口服抗凝剂与华法林在衰弱的心房颤动患者中的有效性和安全性。
Eur Heart J Cardiovasc Pharmacother. 2024 Feb 23;10(2):137-146. doi: 10.1093/ehjcvp/pvad091.
7
Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.直接口服抗凝剂和华法林治疗心房颤动患者的处方模式和结局:真实世界分析。
J Cardiovasc Pharmacol Ther. 2019 Sep;24(5):428-434. doi: 10.1177/1074248419841634. Epub 2019 Apr 29.
8
Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.直接口服抗凝剂与华法林在肾功能谱中的比较:来自 COMBINE AF 的患者水平网络荟萃分析。
Circulation. 2023 Jun 6;147(23):1748-1757. doi: 10.1161/CIRCULATIONAHA.122.062752. Epub 2023 Apr 12.
9
Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.直接口服抗凝剂与华法林在非瓣膜性心房颤动中的围手术期结局。
Circulation. 2018 Oct 2;138(14):1402-1411. doi: 10.1161/CIRCULATIONAHA.117.031457.
10
Use of DOACs in real-world challenging settings: a Delphi Consensus from Italian cardiologists.在现实世界复杂情况下使用直接口服抗凝剂:来自意大利心脏病专家的德尔菲共识。
Minerva Cardioangiol. 2019 Oct;67(5):361-373. doi: 10.23736/S0026-4725.19.04985-5. Epub 2019 Jul 24.

本文引用的文献

1
Time Trends and Treatment Pathways in Prescribing Individual Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: An Observational Study of More than Three Million Patients from Europe and the United States.非瓣膜性心房颤动患者个体口服抗凝药物的开具时间趋势和治疗途径:来自欧洲和美国的超过 300 万患者的观察性研究。
Int J Clin Pract. 2022 Jan 31;2022:6707985. doi: 10.1155/2022/6707985. eCollection 2022.
2
Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1,187,000 patients.衰弱症在房颤患者中的患病率及其对结局的影响:一项纳入 118.7 万名患者的系统评价和荟萃分析。
Ageing Res Rev. 2022 Aug;79:101652. doi: 10.1016/j.arr.2022.101652. Epub 2022 May 31.
3
Use and Prescription of Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Multidisciplinary Consensus Document.老年和体弱房颤患者直接口服抗凝剂的使用与处方:多学科共识文件
J Pers Med. 2022 Mar 15;12(3):469. doi: 10.3390/jpm12030469.
4
The Introduction of Direct Oral Anticoagulants Has Not Resolved Treatment Gaps for Frail Patients With Nonvalvular Atrial Fibrillation.直接口服抗凝剂的引入并未解决非瓣膜性心房颤动虚弱患者的治疗差距。
Can J Cardiol. 2022 Jan;38(1):77-84. doi: 10.1016/j.cjca.2021.09.021. Epub 2021 Dec 20.
5
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.2021年欧洲心律协会心房颤动患者使用非维生素K拮抗剂口服抗凝药实用指南。
Europace. 2021 Oct 9;23(10):1612-1676. doi: 10.1093/europace/euab065.
6
Costs and effects of comprehensive geriatric assessment in primary care for older adults with high risk for hospitalisation.在初级保健中对有高住院风险的老年人进行综合老年评估的成本和效果。
BMC Geriatr. 2021 Apr 21;21(1):263. doi: 10.1186/s12877-021-02166-1.
7
Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.低剂量依度沙班用于高龄房颤患者。
N Engl J Med. 2020 Oct 29;383(18):1735-1745. doi: 10.1056/NEJMoa2012883. Epub 2020 Aug 30.
8
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动诊断和管理指南:欧洲心脏病学会(ESC)心房颤动诊断和管理特别工作组,由ESC欧洲心律协会(EHRA)特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
9
Direct oral anticoagulants for patients aged over 80 years in nonvalvular atrial fibrillation: the impact of frailty.直接口服抗凝剂在非瓣膜性心房颤动高龄患者中的应用:衰弱的影响。
J Cardiovasc Med (Hagerstown). 2020 Aug;21(8):562-569. doi: 10.2459/JCM.0000000000000986.
10
Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study.90 岁或以上接受口服抗凝剂治疗的心房颤动患者:一项多中心观察性研究。
Int J Cardiol. 2019 Apr 15;281:56-61. doi: 10.1016/j.ijcard.2019.01.071. Epub 2019 Jan 25.